Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.49 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.49 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.49 |
| ▸ | PRKCA | P17252 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | ESR1 | P03372 | 1/20 | 0.45 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | F2 | P00734 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25893162 | 1.00 | TDP1 (0.59) | TDP1LMNAALDH1A1ADRB2ADRB1 | |
| SCHEMBL18288405 | 1.00 | TDP1 (0.59) | TDP1LMNAALDH1A1ADRB2ADRB1 | |
| SCHEMBL27719708 | 0.90 | TDP1 (0.66) | TDP1LMNAALDH1A1ADRB2ADRB1 | |
| SCHEMBL17470395 | 0.86 | ALDH1A1 (0.66) | TDP1LMNAALDH1A1ADRB2ADRB1 | |
| SCHEMBL5155769 | 0.85 | TDP1 (0.68) | TDP1LMNAALDH1A1ADRB2ADRB1 | |
| SCHEMBL1073073 | 0.85 | LMNA (0.64) | TDP1LMNAALDH1A1ADRB2ADRB1 | |
| SCHEMBL3162957 | 0.84 | TDP1 (0.66) | TDP1LMNAALDH1A1ADRB2ADRB1 | |
| SCHEMBL1866113 | 0.82 | ALDH1A1 (0.70) | TDP1LMNAALDH1A1ADRB2ADRB1 | |
| SCHEMBL1866116 | 0.82 | ALDH1A1 (0.70) | TDP1LMNAALDH1A1ADRB2ADRB1 | |
| SCHEMBL3391 | 0.82 | ALDH1A1 (0.70) | TDP1LMNAALDH1A1ADRB2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4003988-B1 | 3,6-DIAMINO-PYRIDAZIN-3-YL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS PRO-APOPTOTIC AGENTS | SERVIER LAB (FR) | 2026-05-20 | — | — | EP | disclosed |
| CN-114450283-B | 3, 6-Diamino-pyridazin-3-yl derivatives, pharmaceutical compositions containing them and their use as pro-apoptotic agents | 法国施维雅药厂 | 2024-05-07 | — | — | CN | disclosed |
| US-20230242480-A1 | Alkyne Compound, Vitamin D Compound, Analytical Method, and Production Method | JEOL LTD. (JP) | 2023-08-03 | — | — | US | disclosed |
| US-20220289734-A1 | 3,6-DIAMINO-PYRIDAZIN-3-YL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS PRO-APOPTOTIC AGENTS | LES LABORATOIRES SERVIER (FR) | 2022-09-15 | — | — | US | disclosed |
| EP-4003988-A1 | 3,6-DIAMINO-PYRIDAZIN-3-YL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS PRO-APOPTOTIC AGENTS | Les Laboratoires Servier (FR) | 2022-06-01 | — | — | EP | disclosed |
| CN-114450283-A | 3, 6-diamino-pyridazin-3-yl derivatives, pharmaceutical compositions containing them and their use as pro-apoptotic agents | 法国施维雅药厂 | 2022-05-06 | — | — | CN | disclosed |
| WO-2021018857-A1 | 3,6-DIAMINO-PYRIDAZIN-3-YL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS PRO-APOPTOTIC AGENTS | LES LABORATOIRES SERVIER (FR) | 2021-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220289734-A1 | 3,6-DIAMINO-PYRIDAZIN-3-YL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS PRO-APOPTOTIC AGENTS | CASP3, BAX, CASP2 | TDP1 1707/4885LMNA 117/4885ALDH1A1 1619/4885 |
| US-20230242480-A1 | Alkyne Compound, Vitamin D Compound, Analytical Method, and Production Method | VDR, CYP2R1, CYP24A1 | TDP1 4878/4885LMNA 1250/4885ALDH1A1 452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.